Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2023-06-29 AGM Information
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Kommuniké från årsstämma i Hansa Biopharma AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Kommuniké från årsstämma i Hansa Biopharma AB (publ)" (Communiqué from the Annual General Meeting in Hansa Biopharma AB (publ)) and details the resolutions passed at the meeting held on June 29, 2023. Key decisions mentioned include the approval of financial statements, election/re-election of the board and auditor, approval of remuneration, and adoption of incentive programs. This content directly corresponds to the materials presented or summarized following an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2023-06-29 Swedish
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)' and details the resolutions passed during this meeting, such as the adoption of financial statements, election/re-election of the Board of Directors and auditor, approval of remuneration reports, and adoption of incentive programs. These are core activities and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is a summary/bulletin of the meeting's outcomes, not just a notice to attend or a proxy statement.
2023-06-29 English
Kallelse till årsstämma i Hansa Biopharma AB (publ)
AGM Information Classification · 98% confidence The document is titled "Kallelse till årsstämma i Hansa Biopharma AB (publ)" which translates to "Notice of Annual General Meeting in Hansa Biopharma AB (publ)". It details the date, time, location, registration procedures (including proxy voting and advance voting), the proposed agenda items (which include election of directors, approval of financial statements, and proposals for incentive programs), and the proposals from the Nomination Committee and the Board. This content is the definitive material sent to shareholders to inform them and solicit their votes for the Annual General Meeting (AGM). This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI), which covers materials for general meetings. While it relates to the AGM, the primary function here is the formal notice and solicitation of votes/information, making PSI the most precise fit over AGM-R (which is usually the presentation materials *at* the meeting).
2023-05-29 Swedish
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice to Annual General Meeting in Hansa Biopharma AB (publ)" and details the date, time, location, procedures for participation (in person and by advance voting), the proposed agenda items (including election of directors, approval of financial statements, and incentive programs), and proposals from the Nomination Committee. This content is characteristic of a formal notice sent to shareholders regarding an upcoming Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length is substantial (over 50,000 characters), confirming it is the primary notice document, not just a brief announcement of a report (RPA/RNS).
2023-05-29 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI-MARS 2023' (Interim Report January-March 2023) and contains comprehensive financial statements, including income statements, cash flow data, and balance sheet metrics for the first quarter of 2023. It also includes detailed management commentary, pipeline updates, and operational highlights. As it is a substantive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2023
2023-04-20 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – March 2023' and contains comprehensive financial statements, including a financial summary table with Q1 2023 data, business highlights, clinical pipeline updates, and CEO commentary. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2023
2023-04-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.